title: Targeting miR-375 in gastric cancer.
abstract: BACKGROUND
  Gastric cancer remains a major cancer burden in the world, with a poor 5-year survival rate. It is necessary to develop new effective therapeutic strategies to improve the long-term clinical outcome. MicroRNA (miRNA), a class of small non-coding RNA, has been identified as a key regulator of gene expression, and is implicated in the pathogenesis of gastric cancer.
  
  
  METHODS
  This review summarizes the role of miRNAs in gastric carcinogenesis, with an emphasis on the expression and function of miR-375 in gastric cancer and beyond. It also discusses the opportunities and challenges of miR-375 as a potential therapeutic target for gastric cancer. The genes targeted by miR-375, including JAK2 and 3'-phosphoinositide dependent protein kinase-1 (PDK1), are also candidates for gastric cancer therapy.
  
  
  CONCLUSIONS
  Although radical surgery and rational chemotherapy are still the main treatment for gastric cancer, targeting miRNAs, in combination with other conventional therapies, may serve as a promising therapy strategy to improve the clinical outcome.
authors.affiliation: Zhejiang University School of Medicine, Department of Cell Biology, Program in Molecular Cell Biology, Hangzhou, China.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Xu
authors.forename: Yujie
authors.initials: Y
authors.lastname: Deng
authors.forename: Xiaoyi
authors.initials: X
authors.lastname: Yan
authors.forename: Tianhua
authors.initials: T
authors.lastname: Zhou
mesh_terms: D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics
chemical_list: D035683:MicroRNAs